A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2015

At a glance

  • Drugs N 6022 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Acronyms SNO-1
  • Sponsors N30 Pharma; Nivalis Therapeutics
  • Most Recent Events

    • 23 Nov 2014 Planned End Date changed from 1 Nov 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
    • 23 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
    • 23 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top